BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management

Introduction

Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management relies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT), which is the gold standard.

Limitations of Current Methods

Despite its importance, the efficacy of current methods is limited to 46% due to the lack of tools to guide decision-making.

BraiN20 Overview

BraiN20 is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients' brain viability, thereby predicting who will benefit from EVT.

Intellectual Property Rights

Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow.

Project Goals

TiB aims to implement the following clinical objectives:

1. Validate BraiN20 through clinical trials.
2. Acquire CE-Mark and FDA clearance.
3. Bring BraiN20 to market.

Impact on Stroke Management

By providing real-time and continuous monitoring of brain viability, BraiN20 will accelerate stroke management, predict EVT outcomes, and offer tailored care for each patient.